Figure 2.
![EFS and OS following lenalidomide remission induction therapy vs control induction treatment. EFS (A) and OS (B) for patients receiving remission induction therapy (control group vs lenalidomide [Lena] therapy group). Patients were randomly assigned for their first and second induction cycles of combination chemotherapy without additional lenalidomide (control treatment) or with lenalidomide at 15 mg on days 1 to 21 of both cycles. F, failure (or event).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/5/4/10.1182_bloodadvances.2020003855/1/advancesadv2020003855f2.png?Expires=1724941812&Signature=MWIQI0rS~XCH9EYlbGlu45NIqX5-LeNIgve6kwUdahLyWfrwOd1ioRF8VxVc9tvleA9~qLBcINwa3nIooKvUIw9BC4VrC73icP5Qab~LvOVCHJQp4iJmYDKPfw61CNy-RnZsW8pVEzzrqgn5DFMTmJHu7yf86qjRW3DPFU9~7OsA9g4zHSVkusQryKSNh2CbarsyIxDhYa1eo1vuSQl4MNeIN6~DFe9PuAI03LS~TjNXAK3MW31~HLYAkCa6IqGx94wG7Hkz4B--pCzkkEVnKDgc9-i3uRI10rs-LxWC2cYkliyjoDihH9G35D0TsqiDTiJyilWX42uPhGUhOHXAuQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
EFS and OS following lenalidomide remission induction therapy vs control induction treatment. EFS (A) and OS (B) for patients receiving remission induction therapy (control group vs lenalidomide [Lena] therapy group). Patients were randomly assigned for their first and second induction cycles of combination chemotherapy without additional lenalidomide (control treatment) or with lenalidomide at 15 mg on days 1 to 21 of both cycles. F, failure (or event).